FindTrial
Sign In

To asess the Clinical characteristics, outcomes and comparision of conventional and newer therapies in serpositive Myasthenia Gravis

Clinical characteristics, outcomes and comparison of conventional and newer therapies in seropositive Myasthenia Gravis - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/11/076724
Enrollment
32
Registered
2024-11-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G700- Myasthenia gravis

Interventions

None listed

Sponsors

KASTURBA MEDICAL COLLEGE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Newly Diagnosed And Patients Diagnosed Previously With Myasthenia Gravis 2. Patients Under Regular Follow Up In KMC, Manipal With At Least 2 Follow Up Out Patient Visits

Exclusion criteria

Exclusion criteria: 1. Patients Diagnosed With Myasthenia Gravis And Lost To Follow Up Before 3 Months From Treatment Initiation. 2. Patients Recieving Treatment From Other Medical Centers In Addition To Those Prescribed At Ksturba Hospital

Design outcomes

Primary

MeasureTime frame
Clinical Characteristics , Outcomes And Comparision Of Conventional And Newer Therapies In Seropositive Myasthenia Gravis. MGFA- QMG Score Will Be Used As An Outcome MeasureTimepoint: At The Time Of Recruitment And At 3 Months AND 6 Months Follow Up—

Secondary

MeasureTime frame
Compare Early Vs Late Onset Myasthenia Gravis To Compare Thymomatous Vs Non Thymomatous Achr Positive Myasthenia GravisTimepoint: At The Time Of Recruitment And At 3 Months And 6months Follow Up—

Countries

India

Contacts

Public ContactJavvaji Sowmya

Kasturba Medical College, Manipal

padma1002@gmail.com9901422624

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026